Zytiga
See the following -
In Stunning Win For Open Science, Johnson & Johnson Decides To Release Its Clinical Trial Data To Researchers
Matthew Herper | Forbes Magazine | January 30, 2014
Today, Johnson & Johnson JNJ +0.07% is taking a major step toward changing that, not only for drugs like the blood thinner Xarelto or prostate cancer pill Zytiga but also for the artificial hips and knees made for its orthopedics division or even consumer products. “You want to know about Listerine trials? They’ll have it,” says Harlan Krumholz of Yale University, who is overseeing the group that will release the data to researchers.
- Login to post comments